Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI109301

Endogenous Angiotensin Stimulation of Vasopressin in the Newborn Lamb

Sharon R. Siegel, Richard E. Weitzman, and Delbert A. Fisher

Department of Pediatrics, University of California, Los Angeles, California 90509

Department of Medicine, University of California, Los Angeles, California 90509

Harbor General Hospital Torrance, California 90509

Find articles by Siegel, S. in: PubMed | Google Scholar

Department of Pediatrics, University of California, Los Angeles, California 90509

Department of Medicine, University of California, Los Angeles, California 90509

Harbor General Hospital Torrance, California 90509

Find articles by Weitzman, R. in: PubMed | Google Scholar

Department of Pediatrics, University of California, Los Angeles, California 90509

Department of Medicine, University of California, Los Angeles, California 90509

Harbor General Hospital Torrance, California 90509

Find articles by Fisher, D. in: PubMed | Google Scholar

Published February 1, 1979 - More info

Published in Volume 63, Issue 2 on February 1, 1979
J Clin Invest. 1979;63(2):287–293. https://doi.org/10.1172/JCI109301.
© 1979 The American Society for Clinical Investigation
Published February 1, 1979 - Version history
View PDF
Abstract

The effect of furosemide on plasma renin, vasopressin (AVP), and aldosterone concentrations was studied in 10 control and 6 nephrectomized lambs during the 1st 2 wk of life. In a separate study in 10 newborn lambs, 1-sarcosine-8-alanine-angiotensin II (saralasin acetate, 5 μg/kg per min) was infused alone for 40 min, after which furosemide 2 mg/kg i.v. was injected in association with continuing saralasin acetate infusion.

Plasma renin activity increased from a mean (±SEM) of 21.3±3.4 ng/ml per h in the 10 control lambs to 39.4±8.2 ng/ml per h at 8 min (P < 0.001) and remained high through 120 min after furosemide. Plasma AVP and aldosterone concentrations increased from respective mean values of 2.1±0.4 μU/ml and 12.8±2.5 ng/dl to 9.8±2.0 μU/ml (P < 0.01) and 23.0±7.7 ng/dl (P < 0.05) at 35 min and 13.8±2.1 μU/ml and 23.0±4.4 ng/dl at 65 min after furosemide (each P < 0.01). There was an insignificant AVP response in the 10 lambs treated with angiotensin inhibitor: from a mean base line of 4.7±0.9 to 8.3±2.0 μU/ml at 35 min, and 7.4±2.0 μU/ml at 65 min after furosemide. There was no increase in AVP in the anephric lambs.

The mean increment AVP response from base line in the newborn lambs without saralasin, Δ 10.8±2.0 μU/ml, was greater than in the lambs with saralasin, Δ4.0±1.9 (P < 0.05), and greater than in the anephric lambs, Δ3.3±2.1 μU/ml (P < 0.05). The mean blood pressure fell 6 mm Hg in the 10 control lambs (P < 0.05), 7 mm Hg in the anephric lambs (P < 0.05), and 16 mm Hg in the lambs treated with angiotensin inhibitor (P < 0.05) by 35 min after furosemide. However, the changes in plasma AVP were not related to the fall in blood pressure.

These data support the view that the observed AVP response to furosemide in the newborn lamb was mediated through the renin-angiotensin system.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 287
page 287
icon of scanned page 288
page 288
icon of scanned page 289
page 289
icon of scanned page 290
page 290
icon of scanned page 291
page 291
icon of scanned page 292
page 292
icon of scanned page 293
page 293
Version history
  • Version 1 (February 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts